李 煊 , 许子贤 , 明艳林 . 中草药在防治新型冠状病毒肺炎中的应用[J]. 亚热带植物科学, 2020 , 49(02) : 83 -92 . DOI: 10.3969/j.issn.1009-7791.2020.02.001

[1] Li Q, Guan X, Wu P, Wang X Y, Zhou L, Tong Y Q, Ren R Q, Leung K S M, Lau E H Y, Wong J Y, Xing X S, Xiang N J, Wu Y, Li C, Chen Q, Li D, Liu T, Zhao J, Liu M, Tu W X, Chen C D, Jin L M, Yang R, Wang Q, Zhou S H, Wang R, Liu H, Luo Y B, Liu Y, Shao G, Li H, Tao Z F, Yang Y, Deng Z Q, Liu B X, Ma Z T, Zhang Y P, Shi G Q, Lam T T Y, Wu J T, Gao G F, Cowling B J, Yang B, Leung G M, Feng Z J. Early transmission dynamics in Wuhan, China, of novel Coronavirus–infected pneumonia[J]. New England Journal of Medicine, 2020,382: 1199–1207. [2] Wrapp D, Wang N S, Corbett K S, Goldsmith J A, Hsieh C L, Abiona O, McLellan J S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020,367: 1260–1263. [3] Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2[J]. Plos Pathogens, 2018,14(8): e1007236. [4] Chen Y W, Yiu C B, Wong K Y. Prediction of the SARS-CoV-2(2019-nCoV)3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates[J]. F1000 Res, 2020,9: 129. [5] Guo Y R, Cao Q D, Hong Z S, Tan Y Y, Chen S D, Jin H J, Tan K S, Wang D Y, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status[J]. Military Medical Research, 2020,7: 11. [6] 钟燕春. 中医药预防疫病研究进展[C]//全国中医药博士生创新发展学术论坛论文集. 北京: 中国中医科学院研究生院. 2012. [7] 齐有胜,孙毅坤,刘为萍. 单味中药抗流感病毒研究进展[J]. 中国实验方剂学杂志, 2017,23(14): 210–218. [8] 陈灵,柳芳,王晓霞,陈雨扬,宋红艳,夏敬胜,卢江,陈永刚. 875例新型冠状病毒肺炎中医药治疗的用药规律及药学监护[J]. 中国实验方剂学杂志, 2020,26(12): 35–43. [9] 史鸣飞,王传池,胡镜清. 新型冠状病毒肺炎中药预防方用药规律分析[J/OL]. 世界科学技术–中医药现代化, 2020. http:// kns.cnki.net/kcms/detail/11.5699.R.20200302.1307.004.html. [10] 宗阳,丁美林,贾可可,马世堂,居文政. 基于网络药理学和分子对接法探寻达原饮治疗新型冠状病毒肺炎(COVID-2019)活性化合物的研究[J]. 中草药, 2020,51(4): 836–844. [11] 曹灿,崔瑛,楚玉玺,史银玥,巫晓慧,王晓尧,余万冰. 基于网络药理学与分子对接方法的疏风解毒胶囊治疗新型冠状病毒肺炎(COVID-19)的作用机制与活性成分研究[J]. 中草药, 2020,51(9): 2283–2296. [12] 许嘉慧,薛艳,张炜,陆灏. 基于网络药理学的疏风解毒胶囊治疗新型冠状病毒肺炎(COVID-19)的分子机制探析[J]. 中草药, 2020,51(8): 2015–2023. [13] 沈浮,付中应,吴泳蓉,李玲,赵昱东,夏雨,邝高艳. 基于网络药理学及高通量分子对接研究金花清感颗粒中结合SARS-CoV-2特定靶蛋白的活性化合物干预COVID-19的潜在分子机制[J/OL]. 世界科学技术–中医药现代化, 2020. http://kns.cnki.net/kcms/ detail/11.5699.R.20200421.0949.004.html. [14] 刘钱,贺桢翔,杨慧,刘新燕,曾钦,张梅,刘涛. 基于网络药理学和分子对接法探索肺毒清治疗新型冠状病毒肺炎(COVID-19)的潜在活性成分[J]. 中草药, 2020,51(7): 1713–1722. [15] Zhu N, Zhang D Y, Wang W L, Li X W, Yang B, Song J D, Zhao X, Huang B Y, Shi W F, Lu R J, Niu P H, Zhan F X, Ma X J, Wang D Y, Xu W B, Wu G Z, Gao G F, Tan W J. A Novel Coronavirus from patients with pneumonia in China, 2019[J]. New England Journal of Medicine, 2020,382(8): 727–733. [16] Wu F, Zhao S, Yu B, Chen Y M, Wang W, Song Z G, Hu Y, Tao Z W, Tian J H, Pei Y Y, Yuan M L, Zhang Y L, Dai F H, Liu Y, Wang Q M, Zheng J J, Xu L, Holmes E C, Zhang Y Z. A new coronavirus associated with human respiratory disease in China[J]. Nature, 2020,579(7798): 265–269. [17] Zhou P, Yang X L, Wang X G, Hu B, Zhang L, Zhang W, Si H R, Zhu Y, Li B, Huang C L, Chen H D, Chen J, Luo Y, Guo H, Jiang R D, Liu M Q, Chen Y, Shen X R, Wang X, Zheng X S, Zhao K, Chen Q J, Deng F, Liu L L, Yan B, Zhan F X, Wang Y Y, Xiao G F, Shi Z L. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020,579(7798): 270–273. [18] Xu X W, Wu X X, Jiang X G, Xu K J, Ying L J, Ma C L, Li S B, Wang H Y, Zhang S, Gao H N, Sheng J F, Cai H L, Qiu Y Q, Li L J. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series[J]. BMJ, 2020,368: m606. [19] Chen N, Zhou M, Dong X, Qu J M, Gong F Y, Han Y, Qiu Y, Wang J L, Liu Y, Wei Y, Xia J A, Yu T, Zhang X X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020(395): 507–513. [20] 张荣强,刘辉,李凤英,李向文,刘启玲,李星慧,孙娜,张蓓,史传道. 全球2019冠状病毒病(COVID-19)与甲型流感(2009-H1N1)疫情初期的流行病学对比分析及中医药防治策略研究[J/OL]. 陕西中医药大学学报, 2020. http://kns.cnki.net/ kcms/detail/61.1501.r.20200327.1127.006.html. [21] Huang C L, Wang Y M, Li X W, Ren L L, Zhao J P, Hu Y, Zhang L, Fan G H, Xu J Y, Gu X Y, Cheng Z S, Yu T, Xia J A, Wei Y, Wu W J, Xie X L, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J G, Wang G F, Jiang R M, Gao Z C, Jin Q, Wang J W, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. The Lancet, 2020,395(10223): 497–506. [22] Holshue M L, DeBolt C, Lindquist S, Lofy K H, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber S I, Kim L, Tong S X, Lu X Y, Lindstrom S, Pallansch M A, Weldon W C, Biggs H M, Uyeki T M, Pillai S K. First case of 2019 novel coronavirus in the United States[J]. New England Journal of Medicine, 2020(382): 929–936. [23] Sanders J M, Monogue M L, Jodlowski T Z, Cutrell J B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review[J]. JAMA, 2020. doi:10.1001/jama. 2020.6019 [24] Wang M L, Cao R Y, Zhang L K, Yang X L, Liu J, Xu M Y, Shi Z L, Hu Z H, Zhong W, Xiao G F. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Research, 2020,30(3): 269–271. [25] Devaux C A, Rolain J M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?[J]. International Journal of Antimicrobial Agents, 2020: 105938. [26] Touret F, Lamballerie X. Of chloroquine and COVID-19[J]. Antiviral Research, 2020,177: 104762. [27] Gao J J, Tian Z X, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies[J]. Bioscience Trends, 2020,14(1): 72–73. [28] Caly L, Druce J D, Catton M G, Jans D A, Wagstaff K M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in Vitro[J]. Antiviral Research, 2020: 104787. [29] Lim J, Jeon S, Shin H Y, Kim M J, Seong Y M, Lee W J, Choe K W, Kang Y M, Lee B, Park S J. Case of the index patient who caused tertiary transmission of COVID–19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR[J]. Journal of Korean Medical Science, 2020,35(6): e79. [30] Wang Z, Chen X, Lu Y, Chen F F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment[J]. Bioscience Trends,. 2020,14(1): 64–68. [31] 袁蓉,信琪琪,唐仕欢,丛伟红. 中医整体观指导下的COVID-19治疗——同时着眼于病毒和宿主的疗法[J/OL]. 中国中药杂志, 2020,45(7):1521–1525. [32] 邹本良,李敏,范铁兵,王永炎,边永君,陈素平,陈扬,陈盈盈,丛晓东,董国菊,郭敬,胡力捷,黄璐琦,蒋建新,冷路兴,李斌,李东旭,李浩,李静,吕诚,吕文良,齐文升,苗青,石嘉恒,史华新,王冰,王刚,王健,王微,谢晓磊,缐永悦,徐春艳,徐明,闫蓓,杨金亮,杨志旭,张丽,周振琪,朱浩宁. 中医药治疗重型新型冠状病毒肺炎(COVID-19)经验总结及诊疗方案建议[J/OL]. 中医杂志, 2020. http://kns. cnki.net/kcms/detail/11.2166.r.20200402.1149.002.html. [33] 陈冉,王婷婷,李开铃,尚锐峰,宋杰,张景勍. 免疫调节抗病毒中药的特性与应用[J]. 中草药, 2020,51(6): 1412–1426. [34] 黄浪浪,王建安,魏琦,徐驲,刘中勇. 基于“三因制宜”的全国各省区中医药防治新型冠状病毒肺炎用药规律探析[J/OL]. 中药材, 2020. http://kns.cnki.net/kcms/detail/44.1286.R. 20200327. 1416.002.html. [35] 吴英杰,付小宇,张新雪,赵宗江. 基于“三因制宜”原则探讨新冠肺炎不同中医方案的差异性[J/OL]. 中国实验方剂学杂志, 2020. https://doi.org/10.13422/j.cnki.syfjx.20201326. [36] 周芳,李旭成,张栋,蔡威,周勇,潘泉利,张德德. 从“宣肺解毒、和中化湿”论治新型冠状病毒肺炎[J]. 中医药导报, 2020,26(5): 1–4. [37] 朱亮,徐菲拉,王群星,徐斌. 浙江省金华市防治新型冠状病毒感染肺炎中药处方分析[J].浙江中西医结合杂志, 2020,30(3): 179–181. [38] 张丽娟,范恒,陈瑞,朱习文,王文竹,崔丹丹,郭衍喜,李瑞民. 从临床实践谈清肺排毒汤的合理应用[J/OL]. 中医杂志, 2020. http://kns.cnki.net/kcms/detail/11.2166.R.20200326.1355.002.html. [39] 杨璐,崔换天,刘相国,温伟波,王洪武. 基于网络药理学的小柴胡汤治疗新型冠状病毒肺炎(COVID-19)发热的可行性探讨[J]. 中草药, 2020,51(7): 1761–1775. [40] 王哲义,孙怿泽,曲稔栋,刘碧原,樊竹,田金洲,卢涛. 基于网络药理学的麻杏石甘汤治疗新型冠状病毒肺炎(COVID-19)作用机制探讨[J]. 中草药, 2020,51(8): 1996–2003. [41] 马丽娟,暴正瀚,雷乐庭,王逸飞,朱振宇,王济,王琦,乔延江,郑燕飞,吴志生. 基于数据挖掘和网络药理学的新冠肺炎预防方药组方规律和作用机制研究[J/OL]. 世界科学技术–中医药现代化, 2020. http://kns.cnki.net/kcms/detail/11.5699.R.20200331.0856.014.html. [42] 倪力强,陶弘武,杨小林,张杰,倪行健. 中药预防新型冠状病毒肺炎策略与分析[J]. 中华中医药学刊, 2020,38(4): 8–14. [43] 徐天馥,贺成功,杨坤. 基于网络药理学清肺排毒汤治疗新冠肺炎的物质基础及作用机制研究[J/OL]. 天然产物研究与开发, 2020. http://kns.cnki.net/kcms/detail/51.1335.Q.20200413.1918.018.html. [44] 谢铱子,纪树亮,钟彩婷,詹少锋,黄慧婷,刘小虹. 藿朴夏苓汤治疗新型冠状病毒肺炎的网络药理学分子机制研究[J/OL]. 中药材, 2020. http://kns.cnki.net/kcms/detail/44.1286.R.20200320.1105.002.html. [45] 霍志鹏,刘元雪,郝磊,王玉,何毅,周水平,闫凯境. 藿香正气防治新型冠状病毒肺炎潜在应用的研究进展[J]. 现代药物与临床, 2020,35(3): 405–410. [46] 王毅,李翔,张俊华,薛睿,钱竞扬,张晓慧,张晗,刘清泉,范骁辉,张伯礼. 基于网络药理学的宣肺败毒汤治疗新型冠状病毒肺炎机制研究[J/OL]. 中国中药杂志, 2020. https://doi.org/10. 19540/ j.cnki.cjcmm.20200325.401. [47] 孙凯滨,张新雨,刘静,孙蓉. 小柴胡汤治疗早期新型冠状病毒肺炎(COVID-19)邪热郁肺、枢机不利证功效网络分析与机制预测[J]. 中草药, 2020,51(7): 1750–1760. [48] 刘静,范梦月,孙凯滨,孙蓉. 基于分子对接柴胡桂枝干姜汤干预初期寒湿郁肺型新型冠状病毒肺炎的活性成分及功效作用机制探讨[J]. 中草药, 2020,51(7): 1704–1712. [49] 张宏亮,黄振光,蒋霞,丘岳,黄天敏,林忠秋,刘滔滔. 基于网络药理学研究麻杏石甘汤治疗重型新冠肺炎的作用机制[J/OL]. 中药材, 2020. http://kns.cnki.net/kcms/detail/44.1286.R.20200331.1759.002.html. [50] 张依倩,史嘉雯,刘园华,周浩,蔡晓庆,温晋,刘元雪,任红微,王玉,宋兆辉,何毅,孙鹤,周水平,陈韵岱. 补气活血中药在新型冠状病毒肺炎低氧血症的潜在临床应用价值及其机制浅析[J]. 中草药, 2020,51(6): 1435–1442. [51] 毛昀,苏毅馨,薛鹏,李林潞,朱世杰. 金花清感颗粒治疗新型冠状病毒肺炎作用机制探讨[J/OL]. 中药材, 2020. http://kns. cnki.net/kcms/detail/44.1286.R.20200408.1725.002.html. [52] 邓燕君,刘博文,贺桢翔,刘涛,郑荣蕾,杨安迪,黄澳,李玉婷,徐玉玲. 基于网络药理学和分子对接法探索藿香正气口服液预防新型冠状病毒肺炎(COVID-19)活性化合物研究[J]. 中草药, 2020,51(5): 1113–1122. [53] 王林,杨志华,张浩然,于航星,杨康,付宝慧,杨洪涛. 连花清瘟治疗新型冠状病毒(2019-nCoV)肺炎网络药理学研究与初证[J/OL]. 中药材, 2020. https://doi.org/10.13863/j.issn1001-4454.2020.03.049. [54] 靳晓杰,关瑞宁,毛建军,王燕如,王菲,李潮新,李佳蔚,刘东玲,张志明,刘永琦. 基于计算机辅助药物设计的清肺排毒汤多靶点系统治疗新型冠状病毒肺炎(COVID-19)物质基础探究[J]. 中草药, 2020,51(8): 1984–1995. [55] 赵凰宏,马振,韩冠先,关东升,杨柳,雷励飞,曹钰珂. 基于网络药理学探讨藿朴夏苓汤“培土生金”治疗新型冠状病毒肺炎的潜在作用机制[J/OL]. 中药药理与临床, 2020. https://doi.org/10.13412/j.cnki.zyyl.20200324.001. [56] 杨璐,崔换天,刘相国,温伟波,王洪武. 基于网络药理学的小柴胡汤治疗新型冠状病毒肺炎(COVID-19)发热的可行性探讨[J]. 中草药, 2020, 51(7): 1761–1775. [57] 王哲义,孙怿泽,曲稔栋,刘碧原,樊竹,田金洲,卢涛. 基于网络药理学的麻杏石甘汤治疗新型冠状病毒肺炎(COVID-19)作用机制探讨[J/OL]. 中草药, 2020,51(08): 1996–2003. [58] 黄浪浪,徐驲,刘言薇,刘中勇. 基于网络药理学和分子对接技术的玉屏风散防治新型冠状病毒肺炎活性化合物研究[J/OL]. 中药药理与临床, 2020. https://doi.org/10.13412/j.cnki.zyyl. 20200407.005. [59] 谢平,何少贵,郝春莉,游其华,沈金海,赖源发,赵晶. 基于网络药理学和分子对接法探索玉屏风散治疗新冠病毒肺炎(COVID-19)活性化合物研究[J/OL]. 中药材, 2020. http://kns. cnki.net/kcms/detail/44.1286.R.20200325.0829.002.html. [60] 张春辉,邢雪琨,张慧. 黄芩的药理作用研究[J]. 中兽医医药杂志, 2020,39(2): 98–100. [61] Dinda B, Dinda S, Dassharma S, Banik R, Chakraborty A, Dinda M. Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders[J]. European Journal of Medicinal Chemistry, 2017,131: 68–80. [62] Li L C, Kan L D. Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future[J]. Journal of Ethnopharmacology, 2016,198: 45–63. [63] 周政,朱春胜,张冰. 基于数据挖掘的中医药治疗新型冠状病毒肺炎用药规律研究[J]. 中国中药杂志, 2020,45(6): 1248–1252. [64] 刘伟,龚普阳,顾健,袁志翔. 具解热抗炎、免疫调节作用的中药用于治疗新型冠状病毒肺炎(COVID-19)的探讨[J/OL]. 中药材, 2020. http://kns.cnki.net/kcms/detail/44.1286.R.20200423.0843.002.html. [65] 许洪波,刘妍如,周瑞,于金高,杨宁娟,王梅,黄峰,宋忠兴,唐志书. 基于分子对接和网络药理学技术预测银翘解毒合剂防治新型冠状病毒肺炎的可行性[J/OL]. 中国现代中药, 2020. https://doi.org/10.13313/j.issn.1673-4890.20200311007. [66] 张志美,郭时金,付石军,霍芳,徐倩倩,张颖,王艳萍,沈志强. 金银花活性成分及药理作用研究进展[J].家畜生态学报, 2013,34(6): 89–91. [67] 刘嘉,严宝飞,曾明月,曾庆琪,杨海军,张景正. 黄芩–金银花药对治疗新型冠状病毒肺炎潜在作用机制的网络药理学研究[J]. 世界中医药, 2020,15(4): 502–511. [68] 李彦志,王珑静,龙飞,蒋运斌,闫婕,何郡,赵姝婷,吕光华,凌智群. 基于网络药理学从“湿邪”探讨中医药治疗新型冠状病毒肺炎(COVID–19)的作用机制[J]. 中草药, 2020,51(8): 2004–2014. [69] 程健,姜玉华. 槲皮素通过抑制丝裂原活化蛋白激酶信号通路表达减轻小鼠放射性肺炎[J]. 山东大学学报(医学版), 2019,57(5): 87–92. [70] 徐培平,符林春,张奉学,朱宇同,李际强. 槲皮素抗流感病毒作用研究[J]. 热带病与寄生虫学, 2010,8(2): 66–68. [71] 付成瑞. 山奈酚对小鼠放射性肺损伤防治作用的实验研究[D]. 济南: 济南大学硕士学位论文, 2014. [72] 马青云,刘辰,杜海涛,张贵晟,闫滨,孙启慧,刘孝云,齐冬梅,杨勇,容蓉. 基于高通量分子对接虚拟筛选SARS-CoV-2 3CL水解酶中药小分子抑制剂及抗新型冠状病毒肺炎(COVID-19)的中药及其复方预测[J]. 中草药, 2020,51(6): 1397–1405. [73] 李慧,张林. 苍术治疗新型冠状病毒(2019-nCoV)肺炎分子机制的网络药理学研究[J/OL]. 中药材, 2020. http://kns.cnki.net/ kcms/detail/44.1286.R.20200407.1450.002.html. [74] 杨璐平,盖聪,周梦琪,马浩洁,张宇昕,张锦坤,孙红梅. 麻黄–苍术治疗新型冠状病毒肺炎机制的网络药理学探讨[J/OL]. 中药材, 2020. http://kns.cnki.net/kcms/detail/44.1286.R.20200401.0904.002.html. [75] 陈亚楠,朱星昊,苗明三,孙旭,刘怀民. 中医药防治新型冠状病毒肺炎的用药规律分析[J]. 中国现代应用药学, 2020,37(5): 542–548. [76] Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr H W. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus[J]. Lancet, 2003,361: 2045–2046. [77] Chen H, Du Q. Potential natural compounds for preventing 2019-nCoV infection[J/OL]. Preprints, 2020. doi: 10.20944/ preprints202001.0358.v3 [78] 尉秀清,吴晓瑛. 新型冠状病毒肺炎及在适宜患者中试用甘草甜素治疗的建议[J]. 新医学, 2020,51(3): 168–172. [79] Lin C W, Tsai F J, Lai C C, Wan L, Ho T Y, Hsieh C C, Chao P L. Anti-SARS coronavirus 3C–like protease effects of Isatis indigotica root and plant-derived phenolic compounds[J]. Antiviral Research, 2005, 68: 36–42. [80] Jo S, Kim S, Shin D H, Kim M S. Inhibition of SARS-CoV 3CL protease by flavonoids[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020,35(1): 145–151. [81] Zhuang M, Xiao P, Furuta R, Fujisawa J, Ling H, Hattori T. 中草药对SARS病毒感染的抑制作用[J]. 中国实验动物学报, 2005(S1): 16–17. [82] 张宇实,丛伟红,张晶晶,郭非非,李洪梅. 中草药及其活性成分对人冠状病毒干预作用的研究进展[J]. 中国中药杂志, 2020,45(6): 1263–1271.